spacer
home > ict > winter 2020 > race for children act: product development considerations
PUBLICATIONS
International Clinical Trials

RACE for Children Act: Product Development Considerations




In August 2020, the RACE for Children Act will go into effect. Until now, certain treatments, such as cancer drugs with orphan designation, were exempt under the Pediatric Research Equity Act (PREA). The RACE for Children Act eliminates the orphan exemption for new cancer drugs directed at molecular targets relevant to childrenís cancers.

Complying with the RACE for Children Act and PREA

With the RACE for Children Act, any original new drug application (NDA) or biologics licence application (BLA) submitted on or after 18 August 2020, for a new active ingredient to treat an adult cancer indication with orphan designation, must have an agreed paediatric study plan (PSP) in place (even if the adult indication does not occur in children) if the molecular target is substantially relevant to the growth or progression of a paediatric cancer. More drug developers will now need to consider the implications of PREA. In December 2019, the FDA issued a draft guidance to help companies comply with the new regulations (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Lynne Georgopoulos, RN, MSHS, RAC, is Vice President of Regulatory Affairs and Pediatric Strategic Development at Synteract. She is responsible for providing professional leadership to ensure compliance with FDA, EMA, and ICH regulations in the creation and execution of preclinical, clinical, and regulatory strategies to support paediatric drug development across multiple therapeutic areas. She draws on 30- plus years in clinical operations/development, regulatory affairs, project management, and quality assurance with extensive R&D experience in small molecules and protein therapeutics, from investigational NDA to NDA/BLA.
Print this page
Send to a friend
Privacy statement
News and Press Releases

LYNPARZA (olaparib) Plus Abiraterone Approved in the US for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck & Co., Incís, known as MSD outside the US and Canada, LYNPARZA (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UKís Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement